N Engl J Med 384:403C416

N Engl J Med 384:403C416. the average IgG antibody level increased after the second dose compared to the first dose ( em P /em ? ?0.001). Overall, titers peaked at week 6 for both vaccines. Titers were significantly higher for the mRNA-1273 vaccine on days 14 to 20 ( em P /em ? ?0.05), 42 to 48 ( em P /em ? ?0.01), 70 to 76 ( em P /em ? ?0.05), and 77 to 83 ( em P /em ? ?0.05) and higher for the BNT162b2 vaccine on days 28 to 34 ( em P /em ? ?0.001). In two participants taking immunosuppressive drugs, the SARS-CoV-2 IgG antibody response remained negative. mRNA-1273 elicited higher IgG antibody responses than BNT162b2, possibly due to the higher S-protein delivery. Prospective clinical and serological follow-up of defined cohorts such as this may prove useful in determining antibody protection and whether differences in antibody kinetics between the vaccines have manufacturing S3I-201 (NSC 74859) relevance and clinical significance. IMPORTANCE SARS-CoV-2 vaccines using the mRNA platform have become one of the most powerful tools to overcome the COVID-19 pandemic. mRNA vaccines enable human cells to produce and present the virus spike protein to their immune system, leading to protection from severe illness. Two mRNA vaccines have been widely S3I-201 (NSC 74859) implemented, mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech). We found that, following the second dose, spike protein antibodies were higher with mRNA-1273 than with BNT162b2. This is biologically plausible, since mRNA-1273 delivers a larger amount of mRNA (100?g mRNA) than BNT162b2 (30?g mRNA), which is translated into spike protein. This difference may need to be urgently translated into changes in the manufacturing process and dose regimens of these vaccines. strong class=”kwd-title” KEYWORDS: COVID-19, SARS-CoV-2, BNT162b2, mRNA-1273, vaccine, IgG, antibodies, vaccines INTRODUCTION Within 1?year of the emergence of SARS-CoV-2, two novel and effective mRNA vaccines became available, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) (1, 2). Thirty micrograms of BNT162b2 S3I-201 (NSC 74859) mRNA is translated into the SARS-CoV-2 full-length spike protein (prefusion conformation) and boosted 3?weeks after (3). One hundred micrograms of mRNA-1273 mRNA is translated into the prefusion-stabilized spike glycoprotein and boosted 4?weeks later (4). Healthcare workers were the first group to receive BNT162b2 and mRNA-1273 (1). The present study was launched on 10 December 2020, the week that SARS-CoV-2 vaccines became available, providing the opportunity to assess antibody responses in participants receiving two different vaccine brands, before and after immunization. Most studies so far have focused on following IgG antibody responses to single vaccine brands (5,C8). This study is examining how antibody responses vary by vaccine brand, dosage, and days since vaccination, for a period of 1 1?year minimum. This is the report on the first 3?months of anti-SARS-2-CoV-spike protein IgG antibodies in a cohort of clinicians. Over at least a 1-year period, we will collect three additional time points in an attempt to understand the clinical relevance of antibody levels over time. RESULTS Among 656 clinicians who Mouse monoclonal to CD13.COB10 reacts with CD13, 150 kDa aminopeptidase N (APN). CD13 is expressed on the surface of early committed progenitors and mature granulocytes and monocytes (GM-CFU), but not on lymphocytes, platelets or erythrocytes. It is also expressed on endothelial cells, epithelial cells, bone marrow stroma cells, and osteoclasts, as well as a small proportion of LGL lymphocytes. CD13 acts as a receptor for specific strains of RNA viruses and plays an important function in the interaction between human cytomegalovirus (CMV) and its target cells consented to participate, 611 (93.1%) completed their baseline survey and serum collection. The mean age of participants was 47.4?years. Approximately two-thirds were female (Table?1). Participants self-identified as primarily white (49.8%), Asian (44%), and non-Hispanic (96.2%). Of the 611 participants, 551 (90.2%) completed the 3-month follow-up. Of the 551 participants, 532 (96.6%) tested negative for SARS-CoV-2 IgG at baseline and therefore were found eligible for seroconversion. Of the 532 participants, 217 (40.8%) received BNT162b2 and 315 (59.2%) received mRNA-1273. S3I-201 (NSC 74859) The difference in the size of the groups receiving the two vaccines is explained by the fact that this was not a randomized controlled trial but a measurement of the real-world implementation of vaccine rollout in a clinician population. Clinicians went to.